Related News
Pfizer vaccine may get emergency OK
Print Edition
Pfizer and BioNTech could secure emergency US and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95 percent success rate and no serious side effects, the drugmakers said on Wednesday.
The vaccine鈥檚 efficacy was found to be consistent across different ages and ethnicities, which shows a promising sign given the disease has disproportionately hurt the elderly and certain groups including black people.
The US Food and Drug Administration could grant emergency-use by the middle of December, BioNTech Chief Executive Ugur Sahin said. Conditional approval in the European Union could be secured in the second half of December.
鈥淚f all goes well I could imagine that we gain approval in the second half of December and start deliveries before Christmas, but really only if all goes positively,鈥 he added.
The success rate of the vaccine developed by the US drugmaker and German partner BioNTech was far higher than what regulators had said would have been acceptable.
Of the 170 volunteers who contracted COVID-19 in Pfizer鈥檚 trial involving over 43,000 people, 162 had received a placebo and not the vaccine, meaning the vaccine was 95 percent effective. Of the 10 people who had severe COVID-19, one had received the vaccine.
The final trial analysis comes a week after initial results showed the vaccine was more than 90 percent effective.
BioNTech鈥檚 Sahin said US emergency use authorization would be applied for tomorrow.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
